EF Hutton analyst Tony Butler initiated coverage of Fate Therapeutics with a Buy rating and $16 price target. The company is developing optimized cellular immunotherapies against cancer by first beginning with what Fate believes is the most important ingredient: better cells, Butler tells investors in a research note. The analyst says Fate offers the potential to produce highly uniform cell products from a single iPSC source that can be available off the shelf.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FATE:
- Fate Therapeutics downgraded to Neutral from Buy at Guggenheim
- What’s In Store for Fate Therapeutics Heading into 2023?
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Fate Therapeutics downgraded to Perform from Outperform at Oppenheimer
- Fate Therapeutics initiated with a Sell at Goldman Sachs
